Review

MicroRNAs at the crossroads of cardiovascular disease: Mechanisms, biomarkers, and therapeutic promise

Vibha Rani 1,*

1 Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector 62, Noida, U.P., India.

* Correspondence: vibha.rani@jiit.ac.in (V.R.)

Citation: Rani, V. MicroRNAs at the crossroads of cardiovascular disease: Mechanisms, biomarkers, and therapeutic promise. Glob. Jour. Bas. Sci. 2025, 1(11). 1-8.

Received: July 12, 2025

Revised: August 30, 2025

Accepted: September 10, 2025

Published: September 13, 2025

doi: 10.63454/jbs20000058

ISSN: 3049-3315

Volume 1; Issue 11

Download PDF file

Abstract: MicroRNAs (miRNAs) are a class of small, endogenous, non-coding RNAs that function as critical post-transcriptional regulators of gene expression. By binding to complementary sequences on target messenger RNAs (mRNAs), they typically lead to translational repression or mRNA degradation. In cardiovascular (CV) biology and disease, miRNAs have emerged as central players, orchestrating fundamental processes such as cardiomyocyte development, contractility, apoptosis, hypertrophy, fibrosis, angiogenesis, and lipid metabolism. This review synthesizes current knowledge on the mechanistic roles of specific miRNAs in the pathogenesis of major cardiovascular diseases (CVDs), including coronary artery disease (CAD), myocardial infarction (MI), heart failure (HF), arrhythmias, and hypertension. We further explore the substantial promise of circulating miRNAs as sensitive, specific, and stable biomarkers for early diagnosis, risk stratification, and prognostic assessment. Finally, we critically evaluate the therapeutic potential of miRNA-based strategies—using miRNA mimics to restore deficient miRNAs or anti-miRNAs (antagomirs) to inhibit overexpressed miRNAs—highlighting both the encouraging preclinical results and the significant challenges facing clinical translation. The convergence of miRNAs as mechanistic mediators, diagnostic tools, and therapeutic targets places them at a unique crossroads in the ongoing battle against cardiovascular disease.

Keywords: MicroRNA; cardiovascular disease; biomarkers; gene regulation; heart failure; atherosclerosis; therapeutics

1. Introduction

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, accounting for nearly one-third of all deaths annually [1]. Despite significant advances in pharmacological management, percutaneous interventions, and risk stratification algorithms, major challenges persist. These include the need for earlier detection of subclinical disease, more precise prognostic tools to guide personalized management, and novel therapeutic strategies capable of fundamentally modifying disease progression beyond conventional targets. The molecular complexity of CVD, driven by intricate, dysregulated gene networks, underscores the necessity for a deeper understanding of its pathobiological underpinnings. 

In the past two decades, a class of small non-coding RNAs, known as microRNAs (miRNAs), has revolutionized our understanding of post-transcriptional gene regulation. First discovered in Caenorhabditis elegans for their role in developmental timing, miRNAs are evolutionarily conserved, single-stranded molecules, approximately 22 nucleotides in length [2]. Their canonical function involves binding to partially complementary sequences, primarily within the 3’-untranslated regions (3’UTRs) of target messenger RNAs (mRNAs), leading to translational repression or mRNA destabilization and degradation [1-7]. Through this mechanism, a single miRNA can fine-tune the expression of hundreds of target genes, thereby orchestrating complex biological programs. 

While early research focused on their roles in development and oncology, miRNAs have emerged as indispensable regulators of cardiovascular homeostasis and pathology. They exhibit precise temporal and cell-type-specific expression patterns in the heart and vasculature, governing fundamental processes such as cardiomyocyte growth and contractility, vascular endothelial function, smooth muscle cell phenotype, fibroblast activation, and immune cell recruitment [3, 4]. Consequently, their dysregulation is not merely a secondary epiphenomenon but a central driver in the pathogenesis of major CVDs, including pathological hypertrophy, heart failure (HF), arrhythmogenesis, atherosclerosis, and hypertension [4, 5]. 

The translational potential of miRNA biology operates on two parallel and promising fronts. First, miRNAs are detected in remarkably stable forms in the bloodstream, encapsulated within extracellular vesicles (e.g., exosomes, microvesicles) or complexed with Argonaute proteins or high-density lipoproteins, which protect them from endogenous RNase activity [6]. This stability, coupled with their disease-specific expression signatures, positions circulating miRNAs as a new class of sensitive, accessible, and potentially organ-enriched biomarkers for early diagnosis, risk stratification, and monitoring of therapeutic response. Second, gain- and loss-of-function studies in preclinical models have consistently demonstrated that the experimental modulation of specific miRNAs—either through restoration (using miRNA mimics) or inhibition (using anti-miR oligonucleotides)—can profoundly influence disease phenotypes, offering a compelling rationale for miRNA-based therapeutics [7]. 

This review aims to provide a comprehensive synthesis of the field, navigating the critical crossroads where miRNA biology meets clinical cardiology. We will detail the well-defined mechanistic roles of key miRNAs across the spectrum of cardiovascular pathologies, critically evaluate their burgeoning promise as clinical biomarkers, and assess the current landscape and formidable challenges of translating miRNA-targeting therapies from bench to bedside.

2. Overview of quality systems in pharmaceuticals

2.1. miRNA biogenesis

The journey from a microRNA gene to a functional, mature silencing complex is a multi-step, highly coordinated process that ensures precise regulation. It begins with transcription, predominantly by RNA polymerase II, which generates long primary miRNA transcripts (pri-miRNAs). These pri-miRNAs are capped and polyadenylated, much like protein-coding mRNAs, and they fold into characteristic stem-loop structures. The first critical processing event occurs in the nucleus, where the Microprocessor complex—comprising the RNase III enzyme Drosha and its essential cofactor, the double-stranded RNA-binding protein DGCR8—recognizes and cleaves the base of the pri-miRNA stem-loop. This “cropping” step releases a shorter, approximately 70-nucleotide hairpin known as the precursor miRNA (pre-miRNA) [8-13]. The pre-miRNA is then actively exported to the cytoplasm via Exportin-5, a process dependent on Ran-GTP. Once in the cytoplasm, the pre-miRNA undergoes a second cleavage event orchestrated by another RNase III enzyme, Dicer. Dicer removes the terminal loop, resulting in a transient ~22-nucleotide double-stranded RNA duplex. One strand of this duplex, designated the guide strand, is selectively loaded into the effector complex known as the RNA-induced silencing complex (RISC), while the complementary passenger strand is typically degraded. The guide strand, now the mature miRNA, directs RISC to its target messenger RNAs through sequence complementarity [7]. This elaborate biogenesis pathway is subject to multiple layers of regulation at each step, influencing the final abundance and activity of the miRNA.

Figure 1. Mechanisms of mcroiRNAs in cardiovascular disease.

2.2. Mechanisms of gene regulation 

The mature miRNA, housed within RISC, exerts its regulatory function by binding to specific sequences on target mRNAs. The primary and most well-characterized mechanism involves interaction with partially complementary sites, most frequently located within the 3′ untranslated region (3′ UTR) of the mRNA. This binding is mediated by a core “seed sequence” (nucleotides 2-8 at the miRNA’s 5′ end), which provides the foundational specificity for target recognition. The consequence of this interaction is typically gene silencing, achieved through two interconnected mechanisms: translational repression, where the initiation or elongation of protein synthesis is blocked, and mRNA destabilization, which is often the dominant effect in mammalian cells. Destabilization is primarily driven by miRNA-mediated recruitment of deadenylase complexes that shorten the poly(A) tail, leading to subsequent decapping and exonucleolytic degradation of the transcript [8-13]. While binding to 3′ UTRs is standard, miRNAs can, in less common instances, interact with  sites in the coding sequence or 5′ UTR, and under specific cellular conditions, have even been reported to activate translation, highlighting the contextual nuance of miRNA function (Figure 1). The true regulatory power of miRNAs lies in their capacity to form extensive, interconnected networks. A single miRNA can target hundreds of distinct mRNAs, often coregulating genes within the same biological pathway, thereby enabling potent and coordinated repression of entire cellular programs. Conversely, a single mRNA may contain binding sites for multiple different miRNAs, allowing for combinatorial control and the integration of various signals. This architecture creates robust, tunable regulatory circuits that are crucial for the fine-tuning of gene expression in development, homeostasis, and disease pathogenesis [8].

3. miRNAs in cardiovascular disease pathophysiology

MicroRNAs have emerged as master regulators of cardiac and vascular biology, with their dysregulation representing a central mechanism in the pathogenesis of nearly all major cardiovascular disorders. They function as nodal points in signaling pathways, capable of amplifying or suppressing disease phenotypes by coordinately targeting multiple genes within a network [14-20]. The following sections detail the pivotal roles of specific miRNAs in key pathological processes.

3.1. Cardiac hypertrophy and heart failure

Pathological cardiac hypertrophy, initially an adaptive response to sustained pressure or volume overload, frequently progresses to maladaptive remodeling, systolic and diastolic dysfunction, and ultimately heart failure. This transition is orchestrated by a profound reprogramming of gene expression, heavily influenced by miRNA activity. Muscle-specific miRNAs, known as myomiRs, are critical in this context. miR-1 and miR-133, which are highly expressed in cardiomyocytes, are consistently downregulated in hypertrophic and failing hearts. miR-1 targets key modulators of calcium handling and growth, such as calmodulin and Ras GTPase-activating protein, while miR-133 represses genes involved in fibrosis and hypertrophy, including RhoA and connective tissue growth factor (CTGF). Experimental restoration of these miRNAs has been shown to attenuate pathological growth and improve cardiac function in animal models [9]. Conversely, other miRNAs are upregulated and act as drivers of disease. miR-208a, encoded by an intron of the α-myosin heavy chain (Myh6) gene, is a heart-specific miRNA that forms a regulatory circuit controlling myosin switching. It promotes hypertrophy and fibrosis by repressing targets like thyroid hormone receptor associated protein 1 (Thrap1) and myostatin. Genetic deletion or pharmacological inhibition of miR-208a blunts hypertrophic responses and improves survival in rodent models of pressure overload [10,21-30]. Another key profibrotic regulator is miR-21, which is markedly upregulated in cardiac fibroblasts within failing hearts. It enhances fibroblast survival, proliferation, and extracellular matrix production by targeting Sprouty1 (SPRY1), a negative regulator of the pro-fibrotic ERK-MAP kinase pathway. Inhibition of miR-21 reduces interstitial fibrosis and ameliorates ventricular dysfunction in response to stress, positioning it as a promising anti-fibrotic target [11].

3.2. Myocardial infarction and ischemia–reperfusion injury 

Acute myocardial infarction (MI) initiates a complex cascade of events, including immediate cardiomyocyte death, intense inflammation, and subsequent reparative fibrosis, collectively determining infarct size and the trajectory toward heart failure. miRNAs are rapidly and dynamically regulated during ischemia and reperfusion, critically influencing cell death and repair. The miR-15 family (including miR-15a, miR-15b, miR-16, miR-195, and miR-497) is upregulated in the heart following ischemic injury. These miRNAs act as potent inducers of cardiomyocyte apoptosis by directly targeting a suite of pro-survival genes, most notably Bcl-2. Preclinical studies demonstrate that therapeutic inhibition of the miR-15 family using anti-miR oligonucleotides reduces infarct size, attenuates adverse remodeling, and improves  cardiac function post-MI, highlighting their role as key mediators of cell death [12,31-36]. Post-infarct repair also depends on the restoration of blood flow through angiogenesis, a process tightly regulated by miRNAs. miR-92a, which is expressed in endothelial cells, functions as a negative regulator of angiogenesis by repressing pro-angiogenic mRNAs such as integrin subunit alpha 5 (ITGA5) and sirtuin 1 (SIRT1). Systemic administration of an antimiR-92a following MI in mice and pigs promotes the growth of new blood vessels in the infarct border zone, reduces scar size, and significantly enhances functional recovery, establishing its therapeutic potential [13]. In contrast, miR-126 is an endothelial-enriched miRNA that is essential for maintaining vascular integrity and promoting reparative angiogenesis. It acts through targets like SPRED1 and PIK3R2 to potentiate VEGF and FGF signaling. Its expression is often compromised in cardiovascular disease states, and its downregulation has been associated with impaired neovascularization and worse outcomes after ischemic injury. Delivery of miR-126 mimics has been shown to enhance endothelial progenitor cell function and improve perfusion in models of limb ischemia and myocardial infarction [14].

3.3. Arrhythmogenesis

Cardiac rhythm disturbances involve complex electrical remodeling. miR-1 influences ion channel expression, including the potassium channel Kir2.1 and connexin43, and contributes to arrhythmia susceptibility [15,37-39]. Elevated miR-1 levels in the infarcted heart correlate with ventricular arrhythmias, suggesting a mechanistic link to sudden cardiac death.

3.4. Atherosclerosis and vascular dysfunction

Atherosclerosis is driven by endothelial dysfunction, lipid accumulation, and inflammation. miR-33, co-transcribed with SREBP genes, represses cholesterol efflux transporters ABCA1 and ABCG1; inhibition increases HDL and attenuates plaque progression [16]. miR-155, a regulator of immune cell function, exhibits context-dependent roles—promoting inflammation in macrophages yet limiting atherosclerosis in some models [17]. miR-92a also modulates endothelial activation and pro-atherogenic gene expression, representing a target for vascular protection [18].

4. miRNAs as biomarkers in cardiovascular diseases

The translational potential of miRNAs extends beyond mechanistic insights to their clinical application as novel biomarkers (Figure 2). Their utility hinges on several intrinsic properties: remarkable stability in the harsh environment of biofluids, disease-specific expression patterns that can reflect underlying pathophysiological states, and accessibility through minimally invasive blood sampling [40-53,54-62]. This unique combination positions circulating miRNAs as powerful tools for precision medicine, potentially enabling earlier diagnosis, more accurate risk stratification, and real-time monitoring of therapeutic response. The field has moved from discovery to validation, identifying distinct miRNA signatures associated with specific stages and subtypes of cardiovascular pathology.

The foundational strength of miRNAs as biomarkers lies in their exceptional extracellular stability. Unlike most RNA species, miRNAs in plasma and serum are protected from endogenous RNases by their association with macromolecular complexes. They are found either encapsulated within extracellular vesicles (EVs), such as exosomes and apoptotic bodies shed from cardiovascular cells; bound to RNA-binding proteins like Argonaute 2 (Ago2), the core component of the RNA-induced silencing complex (RISC); or complexed with high-density lipoproteins (HDL) [54, 59, 61]. This packaging not only ensures longevity in circulation but also provides a potential link to their cellular origin and functional state, as EVs can serve as intercellular communication vehicles. Furthermore, their sequences are highly conserved, and sensitive detection methods—including quantitative reverse transcription PCR (qRT-PCR), next-generation sequencing, and microarray hybridization—allow for their precise quantification even at very low concentrations, facilitating clinical assay development [58, 60].

Figure 2. microRNAs as cardiovascular biomarkers.

4.1. Circulating miRNA stability and detection

A key attribute that makes miRNAs viable as biomarkers is their extraordinary stability in extracellular spaces, including blood plasma and serum. Unlike most RNAs, circulating miRNAs are protected from endogenous RNase degradation through their association with macromolecular complexes. They are found either bound to RNA-binding proteins like Argonaute2 (Ago2), the core component of RISC, encapsulated within extracellular vesicles (EVs) such as exosomes and microvesicles shed by cells, or complexed with high-density lipoproteins (HDL) [19]. This packaging not only ensures longevity in the circulation but may also reflect their cellular origin and functional state. Sensitive and accurate detection is paramount for clinical application. Current quantification methods primarily rely on quantitative real-time PCR (qRT-PCR), which offers high sensitivity and specificity, often following stem-loop reverse transcription. For broader profiling, microarray hybridization and next-generation sequencing (NGS) are employed, with NGS providing the advantage of discovering novel miRNA species. Recent advances in digital PCR and nanotechnology-based biosensors promise even greater precision and point-of-care potential.

4.2. miRNA signatures in myocardial infarction

In the context of acute myocardial infarction (MI), circulating miRNAs offer a paradigm-shifting opportunity for early diagnosis. Several cardiomyocyte-enriched miRNAs are released rapidly into the bloodstream upon necrosis and are detectable within 1-3 hours of symptom onset, potentially preceding the rise of conventional biomarkers like cardiac troponin. Key members of this “cardiac-enriched” signature include miR-1, miR-133a/b, miR-208a, and miR-499 [20,63-67]. While miR-208a is almost exclusively cardiac-specific, others like miR-1 and miR-133a are also expressed in skeletal muscle, requiring careful clinical context. The magnitude of their release correlates with infarct size, peak troponin levels, and left ventricular function, providing prognostic information on adverse remodeling and future heart failure risk. Research indicates that a multi-miRNA panel, combining these cardiac-released miRNAs with others reflecting vascular stress or inflammation (e.g., miR-21, miR-126), can significantly enhance diagnostic accuracy and specificity compared to any single biomarker, potentially allowing for earlier therapeutic decision-making.

4.3. miRNAs in heart failure and remodeling

For chronic heart failure (HF), circulating miRNAs hold promise as dynamic biomarkers of disease severity, progression, and therapeutic response. Distinct miRNA profiles have been associated with different HF etiologies (ischemic vs. non-ischemic) and phenotypes (HF with reduced vs. preserved ejection fraction). A landmark study identified miR-423-5p as strongly elevated in HF patients, with levels correlating with disease severity as measured by N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left ventricular ejection fraction, and providing independent prognostic value for mortality [21]. Other miRNAs implicated in myocardial fibrosis and remodeling, such as miR-21 (linked to fibroblast activation) and miR-22 (associated with cardiomyocyte hypertrophy and senescence), also show altered circulating levels that track with the degree of ventricular dysfunction and adverse outcomes. These miRNAs may serve as valuable tools for longitudinal monitoring, offering a “liquid biopsy” of ongoing pathological processes within the myocardium.

4.4. Vascular disease and predictive biomarkers

In atherosclerotic vascular disease, circulating miRNAs can report on endothelial health, plaque inflammation, and stability. miR-126, an endothelial-specific miRNA, is actively secreted in EVs and is critical for vascular integrity. In patients with coronary artery disease (CAD), reduced circulating levels of miR-126 are associated with impaired endothelial function, greater plaque burden, and a significantly increased risk of future major adverse cardiovascular events (MACE) [22]. Conversely, miR-197 has emerged as a predictor of plaque instability; elevated levels in patients with acute coronary syndrome are associated with a higher risk of recurrent events. Other miRNAs, like the pro-inflammatory miR-155, also show promise in reflecting plaque inflammation. The integration of such miRNA profiles with traditional risk scores and lipid metrics could substantially improve the precision of cardiovascular risk stratification, identifying high-risk individuals who might benefit from more aggressive intervention.

4.5. Limitations and standardization

Despite immense promise, the path to routine clinical implementation of miRNA biomarkers faces significant hurdles. Pre-analytical variables—including sample type (serum vs. plasma), collection tubes, centrifugation protocols, and RNA isolation methods—can profoundly influence miRNA measurements and yield conflicting results between studies. The lack of a universal normalization strategy for data analysis (using exogenous spikes, global mean, or specific reference miRNAs) further complicates comparison and validation. Furthermore, population heterogeneity in terms of age, sex, comorbidities (e.g., renal failure, diabetes), and medication use can modulate miRNA levels. Therefore, the field urgently requires standardized operating procedures for sample handling and analysis, followed by large-scale, multi-center prospective cohort studies to rigorously validate the clinical utility, cost-effectiveness, and added value of miRNA biomarkers over existing standards of care. 

5. Therapeutic targeting of miRNAs in cardiovascular diseases

The profound influence of miRNAs on cardiovascular pathophysiology, coupled with their “druggability” via oligonucleotide-based technologies, has established them as a compelling new class of therapeutic targets (Figure 3). The therapeutic paradigm is inherently binary: either inhibiting an overexpressed, pathogenic miRNA (antimiR) or restoring the expression of a deficient, protective miRNA (miRNA mimic) [68-74]. Both strategies aim to rebalance dysregulated gene networks at a nodal level, offering the potential for a more comprehensive therapeutic effect than targeting a single protein.

Figure 3. Therapeutic approaches for targeting microRNAs.

5.1. miRNA inhibition (AntimiRs) 

This strategy utilizes synthetic, single-stranded antisense oligonucleotides engineered to bind with high affinity and specificity to a mature miRNA of interest, sequestering it and preventing its interaction with target mRNAs. To confer nuclease resistance and enhance tissue uptake, these antimiRs are chemically modified. Locked Nucleic Acid (LNA)-modified antimiRs and cholesterol-conjugated antagomirs represent two of the most advanced platforms, offering potent and durable miRNA suppression in vivo. A prime example is antimiR-208a. In rodent models of hypertensive heart disease, systemic administration of an LNA-antimiR against miR-208a effectively prevented pathological hypertrophy, reduced cardiac fibrosis, and improved long-term survival without adverse effects on baseline cardiac function [23]. Similarly, inhibition of the anti-angiogenic miR-92a using a targeted antimiR has been shown to enhance neovascularization, reduce scar size, and improve functional recovery in both murine and porcine models of myocardial infarction, demonstrating translatable proof-of-concept [13]. These preclinical successes validate miRNA inhibition as a viable therapeutic strategy.

5.2. miRNA replacement (miRNA Mimics)

In diseases characterized by the loss of a cardioprotective miRNA, the therapeutic goal is to restore its normal function. miRNA mimics are synthetic, double-stranded RNA duplexes designed to mimic the endogenous mature miRNA. Once delivered into the cytoplasm, one strand is loaded into RISC, reconstituting the lost regulatory activity. For instance, miR-126, a key guardian of endothelial homeostasis, is often downregulated in atherosclerosis and diabetes. Local or systemic delivery of miR-126 mimics in animal models has been shown to accelerate endothelial repair, promote angiogenesis, and attenuate the development of atherosclerotic lesions [24]. In the context of arrhythmogenesis and hypertrophy, restoration of the downregulated miR-1 or miR-133 families using mimics has effectively reduced susceptibility to arrhythmias and blunted the pathological growth response in stressed cardiomyocytes. The mimic approach thus represents a form of “gene therapy” that reinstates a natural regulatory circuit.

5.3. Delivery challenges and strategies

The single greatest hurdle for miRNA-based therapeutics is achieving efficient, targeted, and safe delivery to the relevant cell type within the cardiovascular system. Naked oligonucleotides are rapidly cleared by the kidneys, degraded by nucleases, and can trigger innate immune responses via Toll-like receptor recognition. Systemic administration also raises the risk of off-target effects in non-cardiac tissues. Consequently, significant research is focused on advanced delivery vehicles. These include lipid nanoparticles (LNPs)—technology validated by mRNA COVID-19 vaccines—that can encapsulate and protect oligonucleotides, viral vectors (e.g., adeno-associated viruses) for long-term expression, and conjugation strategies that link antimiRs or mimics to cardiac-homing peptides or antibodies (e.g., against cardiac myosin). The ideal delivery system must balance efficacy, specificity, immunogenicity, and manufacturability.

5.4. Clinical trials and safety

The clinical translation of miRNA therapeutics for cardiovascular disease is in its early but promising stages. Pioneering trials for non-cardiovascular conditions, such as the LNA-antimiR miravirsen (anti-miR-122 for hepatitis C) and cobomarsen (anti-miR-155 for lymphoma), have demonstrated clinical proof-of-concept, acceptable safety profiles, and durable target engagement. For CVD, CDR132L, an LNA-based inhibitor of the pro-hypertrophic miR-132, has progressed through Phase 1 and early Phase 2 trials in patients with heart failure, showing favorable safety signals and preliminary evidence of reverse remodeling [25]. This milestone paves the way for more candidates. However, safety vigilance remains paramount. Potential concerns include off-target gene modulation due to partial sequence homology, saturation of the endogenous RNAi machinery, unintended immune stimulation (e.g., interferon responses), and unknown long-term consequences of chronically altering complex, evolved regulatory networks. Rigorous preclinical toxicology and phased clinical monitoring are therefore essential as this novel drug class advances.

6. Challenges and future directions

Despite the transformative potential of miRNAs in cardiovascular medicine, several formidable challenges must be systematically addressed to translate foundational discoveries into clinical practice. These hurdles span biological complexity, technical standardization, regulatory frameworks, and the integration of miRNA data into the broader healthcare ecosystem.

6.1. Biological complexity

The very feature that makes miRNAs powerful therapeutic targets—their ability to regulate multiple genes within a network—also presents a profound challenge. Each miRNA operates within an intricate, context-dependent web of interactions. A single miRNA can target dozens to hundreds of mRNAs, and its overall effect is determined by the cellular milieu, including the relative abundance of both the miRNA and its targets. Consequently, a miRNA’s role can be cell-type specific and even disease-stage specific; a miRNA that promotes fibroblast activation may simultaneously have beneficial effects in cardiomyocytes, making therapeutic modulation a delicate balancing act. Furthermore, compensatory mechanisms within the regulatory network may dampen the long-term efficacy of targeted interventions. To navigate this complexity, systems biology approaches and computational network modeling are essential. These tools can map miRNA-mRNA interaction networks in specific cardiac cell types, predict off-target effects, and model the system-wide impact of miRNA modulation, thereby enabling more precise and predictable therapeutic design.

6.2. Standardization and clinical validation

For circulating miRNA biomarkers to achieve widespread clinical adoption, the field must overcome significant technical and validation barriers. Currently, variability in pre-analytical factors (sample collection, processing, storage), RNA isolation methods, and detection platforms (qPCR, sequencing) leads to inconsistencies between studies, hindering meta-analyses and direct comparison. A critical need exists for harmonized, standardized protocols endorsed by professional societies. More importantly, the transition from associative studies to clinical utility requires large-scale, prospective, multicenter cohort studies with diverse patient populations. These studies must rigorously demonstrate that miRNA signatures provide incremental prognostic value beyond established clinical scores and biomarkers (e.g., NT-proBNP, troponin), are cost-effective, and can reliably guide therapeutic decisions in a manner that improves patient outcomes.

6.3. Regulatory and ethical considerations

The development of miRNA-based therapeutics and diagnostics occurs within an evolving regulatory landscape. For therapeutics, agencies like the FDA and EMA are adapting frameworks originally designed for small molecules and biologics to accommodate oligonucleotide drugs. Risk-benefit assessments must carefully evaluate potential long-term consequences, including off-target gene silencing, immune activation, and the unknown effects of chronically perturbing endogenous regulatory circuits. For diagnostic biomarkers, regulatory approval requires demonstration of analytical validity (accurate measurement) and clinical validity (association with the condition). Ethically, the use of miRNA profiling raises issues of genetic data privacy, as miRNA patterns can infer physiological and pathological states. Clear policies on data ownership, informed consent for biobanking and profiling, and protection against genetic discrimination are imperative as these tools move closer to clinical use.

6.4. Integration into precision medicine

The ultimate promise of miRNA research lies in its integration into a precision medicine paradigm for cardiology. miRNAs are not isolated signals but one layer in a multi-omic landscape. The future involves integrating dynamic miRNA profiles with static genomic data, proteomic markers, metabolomic signatures, and rich clinical phenotyping from electronic health records and digital health technologies. This multidimensional data fusion will enable the construction of highly refined predictive models for disease onset, progression, and treatment response. Machine learning and artificial intelligence will be indispensable for extracting meaningful, clinically actionable patterns from these high-dimensional datasets. The goal is to move beyond one-size-fits-all therapy towards individualized strategies where a patient’s unique molecular signature, including their miRNA profile, informs the selection of the most effective drug, device, or lifestyle intervention, heralding a new era of personalized cardiovascular care.

7. Conclusion

MicroRNAs have unequivocally established themselves as central molecular conductors at the crossroads of cardiovascular disease, orchestrating the complex symphony of gene expression that underlies health and pathology. Their discovery has illuminated previously opaque layers of regulation, providing a transformative lens through which to view the pathogenesis of conditions ranging from atherosclerosis to heart failure. This review has delineated their tripartite promise: as fundamental mechanistic mediators driving cellular phenotypes, as sensitive circulatory biomarkers offering a real-time window into disease activity and prognosis, and as a novel therapeutic class with the potential to rebalance entire dysregulated networks rather than single protein targets. This convergence of roles places miRNAs in a uniquely pivotal position in the continuum of cardiovascular research and clinical care.

The path from bench to bedside, however, is paved with significant and interlinked challenges. The biological pleiotropy of miRNAs demands sophisticated systems-level understanding to predict therapeutic consequences accurately. The clinical application of biomarkers requires overcoming formidable hurdles in analytical standardization and demonstrating proven clinical utility in diverse, real-world populations through large-scale trials. For therapeutics, the enduring obstacle of targeted, efficient, and safe delivery to the heart and vasculature remains a primary focus of translational bioengineering. Furthermore, the integration of miRNA data into practice necessitates navigating evolving regulatory pathways and ethical considerations surrounding molecular profiling.

Despite these challenges, the trajectory of the field is decidedly forward-moving. Rapid concurrent advances in molecular biology (e.g., single-cell sequencing), bioinformatics (network modeling, AI), nanotechnology (advanced delivery systems), and clinical trial design are collectively constructing the necessary translational bridge. The entry of miRNA-targeted therapies into early-phase clinical trials for heart failure marks a critical inflection point, transitioning the paradigm from compelling preclinical concept to tangible clinical investigation.

Ultimately, realizing the full promise of miRNAs will be an inherently interdisciplinary endeavor. It demands sustained collaboration among basic scientists, clinical cardiologists, bioinformaticians, regulatory experts, and bioengineers. Success hinges on the establishment of rigorous translational frameworks that prioritize robust validation, patient safety, and clear clinical benefit. As these efforts mature, miRNA-guided strategies are poised to become integral components of precision cardiovascular medicine, enabling earlier, more accurate diagnoses and moving therapeutic intervention beyond symptomatic management towards the precise modification of disease pathways, thereby offering new hope in the enduring fight against cardiovascular disease.

Author Contributions: Conceptualisation, V.R.; software, V.R.; investigation, V.R.; writing—original draft preparation, V.R.; writing—review and editing, V.R.; visualisation, V.R.; supervision, V.R.; project administration, V.R. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to the Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector 62, Noida, U.P., India for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO; 2021.
  2. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.
  3. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336–42.
  4. Condorelli G, Latronico MVG, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol. 2014;63(21):2177–87.
  5. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015;101(12):921–8.
  6. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. FEBS J. 2011;278(10):1619–33.
  7. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123(1):11–8.
  8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
  9. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126–39.
  10. Saliminejad K, Khorram Khorshid HR, Soleimani M, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.
  11. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436(7048):214–20.
  12. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248–59.
  13. Liu N, Olson EN. MicroRNA regulatory networks in cardiovascular development. Dev Cell. 2010;18(4):510–25.
  14. Latronico MVG, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol. 2009;6(6):419–29.
  15. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79(4):562–70.
  16. Schroen B, Heymans S. MicroRNAs and beyond: the heart reveals its treasures. Hypertension. 2009;54(6):1189–94.
  17. Bernardo BC, Charchar FJ, Lin RCY, McMullen JR. A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ. 2012;21(3):131–42.
  18. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA. 2008;105(6):2111–6.
  19. Latronico MVG, Elia L, Condorelli G. Noncoding RNAs in cardiovascular disease. Cell Mol Life Sci. 2013;70(22):4025–37.
  20. Gupta SK, Thum T. Non-coding RNAs as orchestrators of autophagy in cardiovascular disease. Cardiovasc Res. 2016;109(2):163–70.
  21. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol. 2014;11(11):655–63.
  22. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613–8.
  23. van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824):575–9.
  24. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–4.
  25. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res. 2013;113(6):676–89.
  26. Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18(5):457–68.
  27. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124(5):2136–46.
  28. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 2012;93(4):573–82.
  29. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res. 2010;3(3):251–5.
  30. Thum T, Bauersachs J, Poole-Wilson PA, et al. The dying heart and the microRNAs. Eur Heart J. 2008;29(24):3029–36.
  31. Boon RA, Dimmeler S. MicroRNAs in myocardial infarction. Nat Rev Cardiol. 2015;12(3):135–42.
  32. Fiedler J, Thum T. MicroRNAs in myocardial infarction. Arterioscler Thromb Vasc Biol. 2013;33(2):201–5.
  33. Porrello ER, Johnson BA, Aurora AB, et al. miR-15 family regulates post-natal mitotic arrest of cardiomyocytes. Circ Res. 2011;109(6):670–9.
  34. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710–3.
  35. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71.
  36. Eulalio A, Mano M, Dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492(7429):376–81.
  37. Luo X, Lin H, Pan Z, et al. MicroRNA-1 modulates arrhythmogenic potential by targeting GJA1 and KCNJ2 in heart. Circulation. 2010;122(23):2377–87.
  38. Cardin S, Guasch E, Luo X, et al. Role for microRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(5):1027–35.
  39. Yang KC, Xiao Q, Zhang X, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2012;125(19):2378–87.
  40. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121(7):2921–31.
  41. Nazari-Jahantigh M, Wei Y, Noels H, et al. MicroRNA-146a controls lipid uptake and FBW7 in atherosclerosis. Proc Natl Acad Sci USA. 2012;109(31):E301.
  42. Hinkel R, Penzkofer D, Zuhlke S, et al. miR-92a regulates endothelial function and atherosclerosis. Circ Res. 2013;112(11):1579–90.
  43. Weber C, Schober A, Zernecke A. MicroRNAs in arterial remodelling, inflammation and atherosclerosis. Curr Drug Targets. 2010;11(8):950–6.
  44. Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res. 2016;118(4):703–20.
  45. Leeper NJ, Raiesdana A, Kojima Y, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol. 2011;226(4):1035–43.
  46. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res. 2007;100(11):1579–88.
  47. Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation. 2012;126(11 Suppl 1):S81–90.
  48. Horie T, Baba O, Kuwabara Y, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque. Circulation. 2012;126(20):2341–53.
  49. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator. Circ Res. 2009;105(2):158–66.
  50. Yang Y, Yang L, Liang X, Zhu G. MicroRNA-155 promotes atherosclerosis by regulating macrophage inflammation. J Cell Biochem. 2015;116(11):2633–42.
  51. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110(3):508–22.
  52. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012;93(4):583–93.
  53. Batkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep. 2012;14(1):79–87.
  54. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.
  55. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110(3):483–95.
  56. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484–8.
  57. Dimmeler S, Zeiher AM. Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur Heart J. 2010;31(22):2705–7.
  58. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30.
  59. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717(1–2):85–90.
  60. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55(11):1977–83.
  61. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–77.
  62. Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120(2):381–99.
  63. Devaux Y, Mueller C, Haaf P, et al. Circulating microRNAs: novel biomarkers with clinical potential in cardiovascular disease. Eur Heart J. 2015;36(2):83–90.
  64. Tijsen AJ, Lorenzen JM, van der Made I, et al. MiR-423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9.
  65. Zampetaki A, Willeit P, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810–7.
  66. Goren Y, Kushnir M, Zafrir B, et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–54.
  67. Dickinson BA, Semus HM, Montgomery RL, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Circ Res. 2013;112(7):1146–54.
  68. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circ Res. 2011;109(4):521–30.
  69. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 2008;105(5):1516–21.
  70. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11):860–72.
  71. Poller W, Fechner H. Development of novel cardiovascular therapeutics from small regulatory RNA molecules. J Mol Cell Cardiol. 2010;49(6):981–3.
  72. Foinquinos A, Batkai S, Genschel C, et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun. 2020;11(1):633.
  73. Nouraee N, Mowla SJ. miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet. 2015;6:232.
  74. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography